Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Allogeneic cardiosphere-derived cells

            Therapeutic Area: Genetic Disease Product Name: CAP-1002

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Capricor Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 12, 2021

            Details:

            Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vamorolone

            Therapeutic Area: Genetic Disease Product Name: VBP15

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: ReveraGen BioPharma

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 24, 2021

            Details:

            In this trial, vamorolone demonstrated efficacy versus placebo over a three-fold dose range of 2 to 6 mg/kg/day versus placebo (p=0.002) and showed for both doses a favorable safety and tolerability profile versus the active control arm of prednisone 0.75mg/kg/day.